Results of Pivotal Catheter Study Published
By MedImaging International staff writers Posted on 18 Jul 2017 |
Image: The Bio2 Medical Angel catheter intended for PE prophylaxis in trauma patients, with contraindication to anticoagulation (Photo courtesy of Bio2 Medical).
The results of a pivotal study for the evaluation of a combined inferior vena cava filter and central venous catheter to prevent pulmonary embolism in critical trauma patients have been published.
The single-arm, multicenter clinical trial showed that the combined catheter resulted in a substantial reduction in clinically significant, as well as fatal cases of Pulmonary Embolism (PE), in critically ill patients.
The combined Angel Inferior Vena Cava (IVC) filter and Central Venous (CV), FDA-cleared catheter was developed by Bio2 Medical (Golden, CO, USA), and the results of the study were published in the June 29, 2017, issue of the Journal of Vascular and Interventional Radiology (JVIR). The catheter was inserted in the Intensive Care Unit (ICU), at the bedside, without fluoroscopy, and retrieved safely, before patient discharge. The study cohort included 163 critically ill patients contraindicated to anticoagulation, all with a high risk of acute PE, from 20 Intensive Care Units (ICUs) in the US.
The results indicated that the Angel Catheter prevented the occurrence of PEs in 11% (14) of 129 patients who had a pre-removal cavogram. The Angel Catheter also impacted PE-related spending reducing the cost of IVC filter removal, and the Interventional Radiology (IR) suite time needed.
Primary investigator of the study, Victor F. Tapson, MD, said, "Acute PE kills more than 100,000 Americans every year, and many more around the world. This study of a combined IVC filter/central venous catheter was the culmination of a panel of dedicated investigators with careful guidance by the FDA. The efficacy and safety of the device, simple bedside placement, and the need to remove it before discharge make it very appealing. Nearly the entire cohort had crucial, yet short-term filter needs so that discharge without a filter was preferred."
Related Links:
Bio2 Medical
The single-arm, multicenter clinical trial showed that the combined catheter resulted in a substantial reduction in clinically significant, as well as fatal cases of Pulmonary Embolism (PE), in critically ill patients.
The combined Angel Inferior Vena Cava (IVC) filter and Central Venous (CV), FDA-cleared catheter was developed by Bio2 Medical (Golden, CO, USA), and the results of the study were published in the June 29, 2017, issue of the Journal of Vascular and Interventional Radiology (JVIR). The catheter was inserted in the Intensive Care Unit (ICU), at the bedside, without fluoroscopy, and retrieved safely, before patient discharge. The study cohort included 163 critically ill patients contraindicated to anticoagulation, all with a high risk of acute PE, from 20 Intensive Care Units (ICUs) in the US.
The results indicated that the Angel Catheter prevented the occurrence of PEs in 11% (14) of 129 patients who had a pre-removal cavogram. The Angel Catheter also impacted PE-related spending reducing the cost of IVC filter removal, and the Interventional Radiology (IR) suite time needed.
Primary investigator of the study, Victor F. Tapson, MD, said, "Acute PE kills more than 100,000 Americans every year, and many more around the world. This study of a combined IVC filter/central venous catheter was the culmination of a panel of dedicated investigators with careful guidance by the FDA. The efficacy and safety of the device, simple bedside placement, and the need to remove it before discharge make it very appealing. Nearly the entire cohort had crucial, yet short-term filter needs so that discharge without a filter was preferred."
Related Links:
Bio2 Medical
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection